Slide 1: MetaStat
4 MetaStat
Slide 2: Forward-Looking Statements
Forward-Looking Statements @ MetaStat entation contains “forward-looking statem er the Securiti change Act of 1934, which are intended to be oor such as within the meaning of the Securities Act of 1933, amended, and the Private Securities Litigation ed by the harbor created thereby. You can identity
Slide 3: MetaStat At-a-Glance
MetaStat At-a-Glance @ MetaStat THE COMPANY MetaStat, Inc. (OTCBB: MTST) 054,418 common shares out.* Market Cap: $77.3M* CORE EXPERTISE Understanding the pathways, mechanics and genetics of CTIVE DIA PROGR ACTIVE THERAPEUTIC RAM CLINICAL BENEFITS systemic metastasis MetaSite Breast™ MenaCale™ MenaBl
Slide 4: Scientific and Clinical Advisors
Scientific and Clinical Advisors @ MetaStat John S. Condeelis, * Director, Tumor Mic Php. Albert Eins «Judith & ichusetts Institute of Technok MIT) Cancer Research at MIT Frank B. Gertler, + Professor of Biology, Ivias Ph_D. ¢ Gertler Lab, David H. Koch Institute for Integrate: Joseph Sparano, * Pro
Slide 5: Senior Management and Directors
Senior Management and Directors @ MetaStat Warren C. Lau Oscar Bronsther, M.D., FACS Daniel Schneiderman David N. Siegel Johan “Thijs’ Spoor PatrickT. Mooney M.D Presic + 15+ years of healthcare and biotechnology managementexperience + 10+ years of healthcare and biotechnology investment banking exp
Slide 6: Why We Are Important
Why We Are Important @ MetaStat is the 1 Significant i in cancer today . System ic metastasis is responsible for 90% of fatalities in solid epithelial cancers « Currently patients’ are both over and under treated because their true metastatic potential can’t be quantified No appro nmercially availab
Slide 7: MetaStat Enables Better Personalized Diagnosis
Metastat Enables Better Personalized Diagnosis @ MetaStat MetaStat’s di the pr | toe curately predict slit Properly identify and differentiate the metastatic risk profile of: ¢ High-risk patients who need aggressive therapy, and ¢ Low-risk patients who can be spared from the harmful side effects and
Slide 8: Unmet Need for Better Diagnostic Markers
Unmet Need for Better Diagnostic Markers 2g MetaStat nation Proliferation (tumor growth) is valuable information, but does notshow the whole picture . ial Tumor grade * Tumorsize + Lymph node involvement (# of nodes) * Hormone status (estrogen (ER), progesterone (PR), HER-2/neu) + Patients age CURRE
Slide 9: Systemic Metastasis
Systemic Metastasis @ MetaStat ( Systemic metastasis is responsible for 90% of cancer deaths Cancer spr s thre * 1. Local infiltration * 2. Lymphatic system * 3. Hematogenous (blood-borne) or “systemic metastasis” information about syste + Focus on Proliferation + Arecorrelative, not causative MetaS
Slide 10: Enormous Market Opportunity
Enormous Market Opportunity @ MetaStat Estimated New Cancer Cases by Sex, U.S., 2012 Breast Lung & Ut Lymphoma (all) emia (all) other sites 134,43¢ 790,740 100% Total new cases per year in the U.S. alone ond most pre ent cane
Slide 11: Diagnostic Portfolio Market Size and Opportunity
Diagnostic Portfolio Market Size and Opportunity @ MetaStat $2.4B Total Annual U.S. Diagnostic Market Opportunity MetaSite MenaCalc MenaCalc MenaCale MenaCalc Breast Breast Lung Prostate Colorectal 229,060. 226,160 241,740 143,460
Slide 12: Increasing Treatment Costs
Increasing Treatment Costs @MetaStat (4 Billic 175 150 125 100 15) 50 Total Cost of Cancer Treatment 2000 2010 2020 Need for Better Diagnosticsand Targeted Therapeutics To help control increasing costs
Slide 13: Understanding and Treating Metastasis
Understanding and Treating Metastasis @ MetaStat MetaSite Breast™ MenaCalc™ MenaBloc™ Diagnostic Platform Diagnostic Therapeutic Measures the Transition AntiMetastatic to Metastatic Cells Therapy ential * Therapeutic with the po fmena * 797 patient trial predicted . survivalin bi wed “the rer elimin
Slide 14: MetaSite Breast - Near Term Product Opportunity
MetaSite Breast™ - Near Term Product Opportunity @ MetaStat at our rete je from a | Easily reproducil it performed (FFPE)t ab on formalin fixed, paraffin em. 3’ tumor biops) + No FDAmarketing approval required * Central reference laboratory (CLIA GLP certification) + Noadditional procedure(s) on the
Slide 15: MenaCalc - Broad Diagnostic Platform
MenaCalc™ - Broad Diagnostic Platform @ MetaStat 1, discontinuous is from a (FINA) ising small amounts of dis: biopsy or fine 1 Broadly applicable: lena and its isoforms are a key regulator of metastatic Tunction in solid epithelial tumors * Encouraging data in breast, prostate and lung cancers Mena
Slide 16: MenaBloc - Targeted Therapeutic Platform
MenaBloc™ - Targeted Therapeutic Platform @ MetaStat Anti-metastatic therapeutic to potentially block or eliminate metast * Positive proof-of-concept data ¢ Results published in Breast Cancer Research (2010) ¢ Deficiency of mena increases survival in PyMT mice 100. 100 3 © Mena WT 8 0 sa) Mena tt 0.
Slide 17: Key Accomplishments
Key Accomplishments @ MetaStat In 2012, MetaStat has accomplished the following: xecuted 2 additional License Agi ents sl a} ctual Property Proved MenaCale diagnostic platform for additional solid epithelial cancers + Encouraging data in adenocarcinoma of the lung and prostate cancers Positive MenaC
Slide 18: Near-Term Milestones
Near-Term Milestones @ MetaStat Key Milestones and Goals for the Next 12 to 24 Months MetaSite Brea ults from 5 atient Large Population Validation Study - (2013) etup CLIA GLP Certified Central Laboratory - (2013) * Publish data from 500 patient Large Population Validation Study in top journal - (20
Slide 19: Investment Highlights
Investment Highlights @ MetaStat Significant unmet clinical n * Systemic meta: is is responsible for 90% of cancer deaths * Currently no diagnostic, prognostic or thera| ic specific to s\ mic metastasis on the market + Patientmisclasitication Itin overtreatment for some and under-treatm ent for othe
Slide 20: Appendix
@MetaStat APPENDIX
Slide 21: Comparable Company
Comparable Company @ MetaStat Genomic Health Inc. (GHDX) Assay pe DX B + 21-gene breast cancer assay commercially introduced in 2004 + Initial marketing with validation results from 660 patients * Provides “Recurrance Score” and likelyhood of chemotherapy benefit * Focused on early stage node negati
Slide 22: Genomic Health
Genomic Health @ MetaStat Sales, COGS and Tests Sold Sales, COGS and Tests Sold $200 000,000 70,000 $180 000,000 60,000 160,000,000 140,000,000 50,000 120,000,000 aeen8 $100 000,000 $80,000,000, 30,000 $60,000,000, 20,000 $40,000,000, 10,000 $20,000,000, | & 2 2004 2005 2006 2007 2008 2009 200 limPr